Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Combined With Intrathecal Chemotherapy in NSCLC With Leptomeningeal Metastasis
NCT04356222Phase 4Unknown
- Start
- Jun 2020
- Primary completion
- Jun 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
01
Overview
A Phase 4 trial of durvalumab in non-small cell lung cancer (NSCLC), leptomeningeal metastasis (LM). Status: unknown.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)leptomeningeal metastasis (LM)
Beyond the preview
Go deeper on NCT04356222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356222.